DJS Antibodies
Headington
About DJS Antibodies
DJS Antibodies is developing novel therapeutics to treat chronic inflammatory diseases. DJS does this through the discovery and development of novel therapeutic monoclonal antibodies against GPCRs. The company's breakthrough technology enables its to produce first-in-class antibody therapeutics to previously intractable disease targets.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $8.0M
- Funding stage: M&A
- Last round: Seed (Dec 2020)
- Website: djsantibodies.com
- Phone: 01865 546471
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/djs-antibodies-98835 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.